Φορτώνει......
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
PURPOSE: Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinom...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Clin Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Clinical Oncology
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4806782/ https://ncbi.nlm.nih.gov/pubmed/25452452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.0703 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|